Allinaire Therapeutics
Company Details
Status: Private
Employees: 1-10
Location:
Beachwood, Ohio, United States
Type:
sample
Technology:
sample
sample
About: Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University.
EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. Based on the pioneering work by the scientific founders, Matthias Clauss, PhD and Irina Petrache, MD, and their colleagues at Indiana University and National Jewish Health, Allinaire Therapeutics and their network of preclinical and clinical scientists, have demonstrated a pivotal pathogenic role of EMAP II in cardiopulmonary diseases, including pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Allinaire Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.